Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2481 • ACR Convergence 2025
Prevalence and Trends of Suicidal Ideation Among Hospitalized Adults with Systemic Lupus Erythematosus (SLE): A National Inpatient Sample Analysis (2016–2020)
Fatima Khdeir and Aysheh Khdeir, ECU Health Medical Center, Greenville, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with psychiatric comorbidities, including depression and suicidal ideation. However, national trends over time have…
Abstract Number: 2451 • ACR Convergence 2025
Tofacitinib Lowers Markers of Photosensitivity in Patients with Cutaneous Lupus Erythematosus
Amy Hurst¹, Mehrnaz Gharaee-Kermani¹, Yuli Cai², Rachael Bogle³, Lin Zhang¹, Amber Young², Craig Dobry¹, Srilakshmi Yalavarthi¹, Jason S. Knight¹, Johann Gudjonsson², Alex Tsoi³, Patricia Rohan⁴, Angela Kibiy⁵, Karen Boyle⁶, Margie Byron⁷, Laura Baird⁷ and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³University of Michigan, Holland, OH, ⁴NIH, Bethesda, MD, ⁵NIH/NIAID, Rockville, MD, ⁶Rho, Inc, Durham, NC, ⁷Rho, Inc., Durham, NC
Background/Purpose: Photosensitivity lowers quality of life in patients with cutaneous lupus erythematosus (CLE) and puts patients with systemic lupus erythematosus (SLE) at risk of systemic…
Abstract Number: 2434 • ACR Convergence 2025
Specificity of Cell-bound T Cell Biomarkers (TC4d, TIgG, TIgM) in Differentiating SLE from ANA-Associated Rheumatic Diseases
Vasileios Kyttaris¹, Sepehr Taghavi², Clayton Nagle³, Christine Schleif³, Brittany Partain⁴ and Tyler O'Malley⁵, ¹Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ²Exagen Inc, Escondido, CA, ³Exagen, Carlsbad, CA, ⁴Exagen, Boston, MA, ⁵Exagen, Vista, CA
Background/Purpose: We previously validated T Cell-bound C4d (TC4d), T Cell-bound IgG (TIgG), and T Cell-bound IgM (TIgM) biomarkers, demonstrating high sensitivity and specificity for differentiating…
Abstract Number: 2416 • ACR Convergence 2025
Direct and Indirect Costs Associated with Damage Accrual: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Megan Barber¹, John Hanly², Murray Urowitz³, Ian Bruce⁴, Yvan St-Pierre⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Juanita Romero-Diaz⁸, Francisco Sanchez-Guerrero⁹, Sasha Bernatsky¹⁰, Daniel Wallace¹¹, David A. Isenberg¹², Anisur Rahman¹², Joan Merrill¹³, Paul Fortin¹⁴, Dafna D. Gladman¹⁵, Michelle Petri¹⁶, Ellen Ginzler¹⁷, Mary Anne Dooley¹⁸, Rosalind Ramsey-Goldman¹⁹, Susan Manzi²⁰, Andreas Jönsen²¹, Graciela Alarcón²², Ronald van Vollenhoven²³, Cynthia Aranow²⁴, Meghan mackay²⁵, Guillermo Ruiz-Irastorza²⁶, S. Sam Lim²⁷, Murat Inanç²⁸, Kenneth Kalunian²⁹, Soren Jacobsen³⁰, Christine Peschken⁸, Diane Kamen³¹, Anca Askanase³² and Ann Clarke¹, ¹Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, United Kingdom, ⁵Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁶Department of Inflammation and Ageing, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom, ⁷Hanyang University Medical Center, Seoul, South Korea, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University Health Network/Sinai Health system, Toronto, ON, Canada, ¹⁰Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹¹Cedars Sinai Medical Center, Studio City, CA, ¹²University College London, London, United Kingdom, ¹³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ¹⁴Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD, ¹⁷SUNY Downstate Health Sciences University, New York, NY, ¹⁸UNC physician network, Chapel Hill, NC, ¹⁹Northwestern University Feinberg School of Medicine, Chicago, IL, ²⁰Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²¹Department of Clinical Sciences, Lund University, Lund, Sweden, ²²The University of Alabama at Birmingham, Oakland, CA, ²³Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands, ²⁴Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ²⁵Feinstein Institutes for Medical Research, Manhasset, NY, ²⁶Biobizkaia Health Research Institute, Barakaldo, Spain, ²⁷Emory University School of Medicine, Atlanta, GA, ²⁸Istanbul University, Istanbul, Turkey, ²⁹UC San Diego, La Jolla, CA, ³⁰Rigshospitalet, Copenhagen, Denmark, ³¹Medical University of South Carolina, Johns Island, SC, ³²Columbia University Medical Center, New York, NY
Background/Purpose: We reported partial direct healthcare costs associated with damage accrual in the SLICC Inception Cohort (Barber M. Arthritis Care Res 2020;72:1800). We have supplemented…
Abstract Number: 2397 • ACR Convergence 2025
Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France
Guillaume Nardella¹, Gerber Gomez², Christian Fischer² and Claire Monat¹, ¹Inovie Labosud Provence, Specialized Autoimmunity Analyses, Marseille, France, ²Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Autoantibodies are key diagnostic markers in autoimmune connective tissue diseases (CTD). Conventional testing often requires multiple single-measurand assays, which can be labor-intensive and time-consuming.…
Abstract Number: 2382 • ACR Convergence 2025
Autoimmune Hemolytic Anemia in SLE: A Real-World National Cohort Study
Bana Shawareb¹, Muhannad Haddadin¹, lindsay Frumker², Keri Ann Pfeil³, Meghan Gump³, Ansaam Daoud⁴ and Omer Pamuk⁵, ¹Cleveland Clinic Akron General, Akron, OH, ²Case Western Reserve University, Cleveland, ³University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ⁴Case Western Reserve University/University Hospitals, Cleveland, OH, ⁵University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Autoimmune hemolytic anemia (AIHA) is a rare but serious hematologic manifestation of SLE. The prognostic implications of AIHA, particularly long-term mortality and organ involvement,…
Abstract Number: 2209 • ACR Convergence 2025
Pregnancy outcomes in Systemic Lupus Erythematosus: Insights from a multicenter Spanish Study on the impact of antiphospholipid antibodies and APS
cristiana Sieiro¹, Jose Ordas Martínez², Ana Merino³, Helena Amar Muñoz⁴, Stefanie Burger⁵, Ignacio Braña Abascal⁵, Carmen Jose Mendéz⁶, Raquel Dos Santos Sobrín⁷, Jose Luis Puga Guzman⁷, Ricardo Blanco⁸ and Víctor Taboada Martínez³, ¹Univrsity of Manchester, Manchester, United Kingdom, ²Complejo Asistencial Universitario de León, León, Spain, ³Hospital Universitario Marqués de Valdecilla, Santader, Spain,, Santander, Spain, ⁴Hospital General Universitario Gregorio Marañón, Rheumatology, Madrid, Spain, Madrid, Spain, ⁵Hospital Universitario Central de Asturias, Rheumatology, Oviedo, Spain, Oviedo, Spain, ⁶Complexo Hospitalario Universitario A Coruña, Rheumatology, A Coruña, Spain, Coruña, Spain, ⁷Hospital Universitario de Santiago de Compostela, Rheumatology, Santiago de Compostela,, Santiago de Compostela, Spain, ⁸Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Pregnancy in patients with systemic lupus erythematosus (SLE) is associated with significant maternal and obstetric risks, particularly in the context of antiphospholipid syndrome (APS).…
Abstract Number: 1931 • ACR Convergence 2025
COSMOS Prevalence of aTTP in SLE
Nisha Sapkota¹, Yevheniia Andriushchenko², Saadia Malik², Sarang Choi² and Sima Terebelo², ¹Interfaith Medical Center, One Broolyn Health, Brooklyn, NY, ²Brookdale Hospital Medical Center, One Brooklyn Health, Brooklyn
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with diverse manifestations, including thrombotic thrombocytopenic purpura (TTP), a life-threatening hematologic disorder. The pathogenesis of…
Abstract Number: 1850 • ACR Convergence 2025
First American SLE patients demonstrate enhanced lipid metabolism and B cell activation by high-content proteomic analyses
Rufei Lu¹, Tayte Stephens², Carla Guthridge¹, Miles Smith¹, Joseph Kheir¹, Cristina Arriens¹, Joan Merrill³, Marci Beel⁴, Susan Macwana¹, Wade DeJager⁵, Nicholas Domingez¹, Teresa Aberle¹, Joel Guthridge¹ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Science Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁴Oklahoma Medical Research Foun, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are autoimmune diseases with overlapping yet distinct immunopathologies. Proteomic profiling of soluble plasma factors can reveal…
Abstract Number: 1830 • ACR Convergence 2025
Single-Cell and Spatial Profiling Reveal Proinflammatory and Profibrotic Fibroblast-Macrophage Niches in Lupus Nephritis
Chirag Raparia¹, Paul Hoover², Nir Hacohen³, Arnon Arazi⁴ and Anne Davidson¹, ¹Feinstein Institutes for Medical Research, Manhasset, NY, ²Brigham and Women's Hospital, Boston, MA, ³Broad Institute of MIT Harvard, Cambridge, MA, ⁴Feinstein Institutes for Medical Research, Acton, MA
Background/Purpose: Lupus nephritis (LN) is a severe complication of SLE that can progress to chronic kidney disease, renal fibrosis, and eventual renal failure. Fibroblasts activated…
Abstract Number: 1719 • ACR Convergence 2025
Impact of SGLT2 Inhibitors on Cardiovascular Events, Mortality, and Lupus Nephritis in Patients with Systemic Lupus Erythematosus and Diabetes: Retrospective Cohort Study
Rusudan Tskitishvili¹, Abdallah Hussein², Nanuka Tsibadze³, Shatha Shahwan⁴ and Priju Varghese², ¹Virtua Health, Camden, NJ, ²Virtua Health, Camden, ³Jefferson Health - Einstein, Philadelphia, PA, ⁴Jordan University of Science and Technology, Jordan
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with increased risks of cardiovascular events, renal complications, and premature mortality. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown cardiorenal…
Abstract Number: 1640 • ACR Convergence 2025
Physical Function and Performance in SLE: A Comparison of Two Population-Based Cohorts
Jessica Fitzpatrick¹, Mrinalini Dey², C. Barrett Bowling³, S. Sam Lim⁴, Courtney Hoge⁵, Charmayne Dunlop-Thomas⁵, Maria Dall'Era⁶, Patti Katz⁷, Jinoos Yazdany¹ and Laura Plantinga⁸, ¹UCSF, San Francisco, CA, ²Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ³Duke University, Durham, NC, ⁴Emory University School of Medicine, Atlanta, GA, ⁵Emory University, Atlanta, GA, ⁶Division of Rheumatology, University of California, San Francisco, CA, ⁷UCSF, San Rafael, CA, ⁸University of California, San Francisco, San Francisco, CA
Background/Purpose: Physical function and performance are top priorities to individuals with systemic lupus erythematosus (SLE). Suboptimal physical function and performance are associated with disability, loss…
Abstract Number: 1541 • ACR Convergence 2025
Tofacitinib versus Belimumab in maintenance therapy of Systemic Lupus Erythematosus: A Real-World Study of the CSTAR cohort
Qizhi Yuan¹, Qinli Qin², Leyao Ma¹ and Mengtao Li³, ¹Peking Union Medical College Hospital, Beijing, China (People's Republic), ²Dongguan Kanghua Hospital, Dongguan, Guangdong, China (People's Republic), ³Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with multi-organ involvements and recurrent relapses. The objectives of treatment include ensuring long-term patient survival, preventing…
Abstract Number: 1521 • ACR Convergence 2025
Kidney-Related Outcomes With Obinutuzumab in Patients With Active Lupus Nephritis: A Pre-Specified Exploratory Analysis of the Clinical Trial Data
Brad Rovin¹, William Pendergraft², Liz Lightstone³, Eric Daugas⁴, Richard Furie⁵, Theodore Omachi², Imran Hassan⁶, Elsa Martins⁷, Thomas Schindler⁷, Jay Garg², Luis Quintana⁸, Piotr Leszczyński⁹ and Ana Malvar¹⁰, ¹The Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁴Department of Nephrology, Hospital Bichat - Claude-Bernard, Paris, France, ⁵Division of Rheumatology, Northwell Health, Great Neck, NY, ⁶Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸Department of Nephrology, Hospital Clinic, Barcelona, Spain, ⁹Department of Internal Medicine and Metabolic Diseases, Poznan University of Medical Sciences, Poznan, Poland, ¹⁰Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: Lupus nephritis (LN) is the most common, severe, organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, double-blind, placebo-controlled, Phase III REGENCY trial (NCT04221477)…
Abstract Number: 1500 • ACR Convergence 2025
Prognostic Impact of Thrombocytopenia on Morbidity and Mortality in Systemic Lupus Erythematosus: A Retrospective Single-Center Study
Milad Heydari-Kamjani¹, Amir Daneshvar², Dana Nachawati², Elleson Harper², Keri Ann Pfeil², Meghan Gump², Lindsay Frumker³ and Omer Pamuk¹, ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ³University hospitals Cleveland medical center, Highland Heights, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with heterogeneous hematologic manifestations. Thrombocytopenia (TP) in SLE may be associated with major organ involvement…

« Previous Page
1
…
7
8
9
10
11
…
181
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].